Targeted Therapy

Targeted Therapy

196 Research news
 
 
Article
Herceptin Biosimilar Seems as Effective as Herceptin

A study suggests that a drug that is a biosimilar to Herceptin, called MYL-1401O, is as effective as Herceptin and has similar side effects.

Jan 3, 2017 | Diagnosis and Targeted Therapy
 
Article
New Chemo Meds Improve Survival for Women With Advanced-Stage Disease

Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.

 
Article
Tykerb May Treat Herceptin-Resistant HER2-Positive Breast Cancer

Research on cells suggests that HER2-positive breast cancers resistant to Herceptin may respond to Tykerb.

 
Article
FDA Approves Talzenna to Treat Metastatic Breast Cancer in Women With BRCA Mutations

The FDA has approved Talzenna (chemical name: talazoparib) to treat locally advanced or metastatic HER2-negative breast cancer in women with an inherited BRCA1 or BRCA2 mutation.

 
Article
Is 9 Weeks of Herceptin as Good as 1 Year of Herceptin?

While 9 weeks of Herceptin was associated with fewer heart problems compared to 1 year of Herceptin, the difference in disease-free survival was small and the researchers said 1 year of Herceptin should remain the standard of care.

Oct 29, 2018 | Diagnosis and Targeted Therapy
 
Article
Injectable Herceptin Shows Promise

A study suggests that an injectable form of Herceptin works just as well as and is as safe as the standard IV form of Herceptin to treat HER2-positive, early-stage breast cancer before surgery.

 
Article
Herceptin Approved in Europe to Treat Breast Cancer

Herceptin plus hormonal therapy for advanced breast cancer is approved in Europe.

May 3, 2007 | Diagnosis and Targeted Therapy
 
Article
If Cancer Stops Responding to Herceptin, It May Have Switched From HER2-Positive to HER2-Negative

A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.

 
Article
Experimental Targeted Therapy May Help Treat People With Advanced-Stage Cancer Due to Abnormal BRCA Gene

A study found that more than 25% of people with an abnormal BRCA1 or BRCA2 gene being treated for advanced-stage breast, ovarian, pancreatic, or prostate cancer got some benefit from olaparib, an experimental targeted therapy medicine.

 
Article
Herceptin Plus Taxol Seems to Reduce Recurrence Risk of Small HER2-Positive Cancers

A small, early study suggests that a combination of Herceptin and Taxol seemed to reduce the risk of recurrence of small HER2-positive breast cancers that hadn't spread to the lymph nodes.

 
Article
Chemo Plus Herceptin Can Put Metastatic, HER2-Positive Disease Into Remission

Some metastatic, HER2-positive breast cancers will respond to Herceptin for several years, suggesting that long-term remission is possible.

 
Article
Experts Say No to Avastin for Breast Cancer

An FDA expert panel recommended that Avastin not be used to treat advanced breast cancer. But doctors may still recommend the medicine depending on a woman's unique situation.

Dec 6, 2007 | Diagnosis and Targeted Therapy
 
Article
Herceptin Plus Taxol Reduces Recurrence Risk of Small HER2-Positive Breast Cancers

Results from an early study suggest that a combination of Herceptin and Taxol reduce the risk of recurrence of small HER2-positive breast cancers that haven't spread to the lymph nodes.

 
Article
Long-Term Results Show Herceptin Offers More Benefits Than Risks for Early-Stage Breast Cancer

A study has found that Herceptin only slightly increases the risk of heart problems in women diagnosed with early-stage, HER2-positive disease.

Oct 14, 2015 | Diagnosis and Targeted Therapy
 
Article
Perjeta Boosts Overall Survival in HER2-Positive Metastatic Breast Cancer

Final results from the CLEOPATRA study showed that women diagnosed with HER2-positive metastatic breast cancer who got Perjeta, Herceptin, and Taxotere lived about 1.5 years longer than women who got only Herceptin and Taxotere.

 
Article
Older Women Treated With Herceptin Need Better Heart Monitoring

Herceptin may cause heart problems; still, a study has found that most older women being treated with Herceptin don't receive heart monitoring that follows current guidelines.

 
Article
ASCO Issues Guidelines on Using Biomarkers to Make Adjuvant Treatment Decisions for Women Diagnosed With Early-Stage Invasive Disease

ASCO has put out new guidelines on using biomarkers to make decisions about treatments after surgery for women diagnosed with early-stage invasive breast cancer.

 
Article
New Type of Targeted Therapy May Help Treat Triple-Negative Disease

Experimental targeted therapy medicines -- called PARP inhibitors -- may make chemotherapy work better against aggressive forms of breast cancer and also may be able to treat breast cancer alone, without chemotherapy.

 
Article
Experimental T-DM1 May Help Treat Metastatic, HER2-Positive Disease

A small, early study suggests that T-DM1, an experimental medicine, may be a better first treatment for women diagnosed with metastatic, HER2-positive breast cancer than a combination of Herceptin and Taxotere.

Oct 8, 2010 | Diagnosis and Targeted Therapy
 
Article
FDA Turns Down Accelerated Approval Request for T-DM1

The FDA has decided to not consider accelerated approval for T-DM1 to treat HER2-positive, advanced-stage breast cancer based on research results available as of August 2010.

Aug 27, 2010 | Diagnosis and Targeted Therapy
 
Article
New Guidelines for Early-Stage Breast Cancer Recommend Treatment Based on Individual Cancer Characteristics

A large group of cancer experts created new guidelines for treating early-stage breast cancer; the guidelines recommend that chemotherapy, targeted therapies, radiation therapy, and hormonal therapy should be based on the characteristics of each individual cancer being treated.

 
Article
Herceptin Plus Perjeta Slightly Better for High-Risk, HER2-Positive Disease Than Herceptin Alone

Adding Perjeta to Herceptin and chemotherapy after surgery to treat early-stage, HER2-positive breast cancer slightly improves survival; women diagnosed with high-risk, HER2-positive, early-stage disease got more benefits.

Jun 16, 2017 | Diagnosis and Targeted Therapy
 
Article
Experimental Combo of Herceptin and Maytansine May Help Treat Metastatic HER2-Positive Breast Cancer

An experimental treatment combining Herceptin and maytansine shows some promise for treating metastatic breast cancer.

Dec 15, 2009 | Diagnosis and Targeted Therapy
 
Article
Another Biosimilar Seems as Safe and as Effective as Herceptin

A biosimilar to Herceptin, called ABP 980, seems as safe as and as effective as Herceptin.

Jul 3, 2018 | Diagnosis and Targeted Therapy
Showing 24 of 196